immunocore-logo-2018
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
May 29, 2024 07:00 ET | Immunocore Holdings plc
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,...
immunocore-logo-2018
Immunocore reports first quarter financial results and provides a business update
May 08, 2024 07:00 ET | Immunocore Holdings plc
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7...
immunocore-logo-2018
Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial
October 21, 2023 08:45 ET | Immunocore Holdings Limited
Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01...
immunocore-logo-2018
Immunocore announces upcoming presentation and posters at ESMO 2023
October 06, 2023 07:01 ET | Immunocore Holdings Limited
Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a...
immunocore-logo-2018
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria,...
immunocore-logo-2018
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion ...
immunocore-logo-2018
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
April 18, 2023 07:00 ET | Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...
immunocore-logo-2018
Immunocore to present four posters at AACR Annual Meeting 2023
March 14, 2023 16:30 ET | Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
immunocore-logo-2018
Immunocore is awarded the Prix Galien France award for KIMMTRAK
December 15, 2022 06:00 ET | Immunocore Holdings Limited
Immunocore is awarded the Prix Galien France award for KIMMTRAK Treatment for unresectable or metastatic uveal melanoma, a rare and aggressive form of cancer affecting the eye. (OXFORDSHIRE,...
immunocore-logo-2018
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
August 03, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3 August 2022) Immunocore Holdings plc...